Loading...
A New Synuclein-Transgenic Mouse Model for Early Parkinson's Reveals Molecular Features of Preclinical Disease.
Hendrickx, Diana M Garcia, Pierre Ashrafi, Amer Sciortino, Alessia Schmit, Kristopher J Kollmus, Heike Nicot, Nathalie Kaoma, Tony Vallar, Laurent Buttini, Manuel
Hendrickx, Diana M
Garcia, Pierre
Ashrafi, Amer
Sciortino, Alessia
Schmit, Kristopher J
Kollmus, Heike
Nicot, Nathalie
Kaoma, Tony
Vallar, Laurent
Buttini, Manuel
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2020-09-30
Submitted date
Files
Loading...
Open Access publication
Adobe PDF, 3.53 MB
Other Titles
Abstract
Understanding Parkinson's disease (PD), in particular in its earliest phases, is important for diagnosis and treatment. However, human brain samples are collected post-mortem, reflecting mainly end-stage disease. Because brain samples of mouse models can be collected at any stage of the disease process, they are useful in investigating PD progression. Here, we compare ventral midbrain transcriptomics profiles from α-synuclein transgenic mice with a progressive, early PD-like striatal neurodegeneration across different ages using pathway, gene set, and network analysis methods. Our study uncovers statistically significant altered genes across ages and between genotypes with known, suspected, or unknown function in PD pathogenesis and key pathways associated with disease progression. Among those are genotype-dependent alterations associated with synaptic plasticity and neurotransmission, as well as mitochondria-related genes and dysregulation of lipid metabolism. Age-dependent changes were among others observed in neuronal and synaptic activity, calcium homeostasis, and membrane receptor signaling pathways, many of which linked to G-protein coupled receptors. Most importantly, most changes occurred before neurodegeneration was detected in this model, which points to a sequence of gene expression events that may be relevant for disease initiation and progression. It is tempting to speculate that molecular changes similar to those changes observed in our model happen in midbrain dopaminergic neurons before they start to degenerate. In other words, we believe we have uncovered molecular changes that accompany the progression from preclinical to early PD.
Citation
Mol Neurobiol. 2020 Sep 30. doi: 10.1007/s12035-020-02085-z. Epub ahead of print.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
EISSN
1559-1182
ISBN
ISMN
Gov't Doc #
Sponsors
License
Attribution-NonCommercial-ShareAlike 4.0 International